Clinical Trial Update: Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML [Phase 2]

View source ↗

Summary

Ongoing Phase 2 study evaluating the safety and efficacy of RVU120 in combination with venetoclax for relapsed/refractory acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• RVU120 (SEL120)
• Venetoclax (venetoclax)

Snippet

Sponsor: Ryvu Therapeutics SA | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING